HomeBusinessHealthcareBuy Ratings On Merck (MRK) & Tcr2 Therapeutics (TCRR)
Buy Ratings On Merck (MRK) & Tcr2 Therapeutics (TCRR)

Merck & Co. (MRK) is testing a new prostate cancer drug and successful drug studies to fight liver cancer and melanoma. Tcr2 Therapeutics (TCRR) is turning focus to ovarian cancer and has a large addressable market. "Merck has dominance in the oncology space with KEYTRUDA. There has been a flight to quality stocks like MRK in a rising interest rate environment. Tcr2 Therapeutics works on the cell therapy side," says Mara Goldstein.

Market On Close

03 Oct 2022

ON AIR
11:00 pm
Trading 360
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
education
3:30 pm
Your First Trade
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
education
7:00 pm
Your First Trade
REPLAY
7:30 pm
Trading 360
REPLAY
8:30 pm
Fast Market
REPLAY
9:30 pm
Next Gen Investing
REPLAY
education
10:30 pm
Your First Trade
REPLAY
ON AIR
11:00 pm
Trading 360
REPLAY

Get Market Minute

Daily insights for every investor

FOLLOW US